Hm Payson & CO Phathom Pharmaceuticals, Inc. Transaction History
Hm Payson & CO
- $5.79 Billion
- Q4 2024
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$44.5 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$32.8 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$31.1 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$16.2 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$15.4 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $172M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...